Document:

Amended Agreement

 Exhibit 10.29 
  

	**	Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under
Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. 

  

					
		  	 Worldwide Research
	  	
		  	 Pfizer Inc.
	  	
		  	 50 Pequot Avenue MS 6025-C5133
	  	
		  	 New London, CT 06320
	  	
		  	 Tel 860 732 0509 Fax 860 715 7747
	  	
		  	 Email b_j_bormann@groton.pfizer.com
	  	
			
	

	  	Global Research & Development	  	
			
	 December 10, 2004
	  		  	
			
		  	B.J. Bormann, Ph.D.	  	
		  	 Vice President
	  	
		  	 Strategic Alliances
	  	

 Dr. B.J. Bormann 
 Vice President 
 Head of Strategic Alliances 
 Pfizer Inc. 
 50 Pequot Avenue 
 New London, CT 06320 
 RE: Second Amending Letter of Agreement between Pfizer Inc. and Immunicon Corporation 
 Dear Dr. Bormann: 
 Immunicon Corporation (“Immunicon”)
wishes to amend the agreement between Pfizer Inc. and its Affiliates (“Pfizer”) and Immunicon, executed on February 10, 2003 having a termination date of February 10, 2004, and subsequently amended effective March 23, 2004
to terminate on February 10, 2005 (as amended, the “2003 Agreement”). We now wish to revise Appendix A, as attached to this letter, and to further extend the Term of the 2003 Agreement to make the termination date the sooner of
February 10, 2006 or the termination of the clinical research study contemplated in the revised Appendix A. 
 All other terms and conditions of the
2003 Agreement, except as set forth above, shall remain unchanged and in full force and effect for the remainder of the Term. 
 If you are in agreement with
the foregoing, please so indicate by signing duplicate copies of this letter in the space provided below, and return one fully signed copy to us, to the attention of Dr. Avijit Roy, Director, Business Development. 
  

									
	 Sincerely,
	 		 	
				
	/s/ Edward L. Erickson	 		 		 	
	 Immunicon Corporation
	 		 	 Acknowledged and Agreed:

	 Edward L. Erickson.
	 		 	 Pfizer, Inc.

	 Chairman, President and CEO
	 		 	
				
		 		 	By:	 	 /s/ B.J. Bormann

		 		 		 	 Name:
	 	 B.J. Bormann

		 		 		 	 Title:
	 	 Vice President

		 		 		 	 Date:
	 	 12/10/2004

 Exhibit A 
 Rationale 
 The implementation of pharmacodymanic markers as decision points in the development of oncology products requires
access to specimens collected during clinical trials as well as access to specimens collected at pilot or methodology studies for biomarker development. Two major obstacles are presented to the implementation of this strategy: clinical feasibility
and technical feasibility. The major obstacle to clinical feasibility is sample access, whereas lack of sensitivity is the major technical limitation. The use of highly sensitive methods of assessment of tumor and other rare cells (e.g. tumor
antigen specific CTLs) may be able to overcome some of these limitations. 
 Importantly, since the collection of blood samples, in a number that does not
affect patient safety, is not considered a burden to the implementation of oncology trials, it may be anticipated that, in addition to the specific project samples that would be directly procured and analyzed during this agreement, a successful
collaboration with Immunicon may indirectly have an overall impact on the feasibility of a biomarker strategy implementation in a mulittude of oncology programs. 
 Background 
 Immunicon is the developer of the CellTracks system. In the CellTracks system, cell analysis is undertaken in a
single step of immunomagnetic selection and alignment. Specific cell targets are recognized by magnetically and fluorescent-labeled reagent antibodies coupled to nanoparticle probes and detected using the CellSpotter Analyzer, a four color
semi-automated fluorescent microscope. Image frames covering the entire surface of a cartridge are captured for each of four fluorescent filter cubes. The captured images containing objects that meet predetermined criteria are automatically
presented in a web-enabled browser from which final selection of cells is made by the operator. The criteria for an object to be defined as a CTC include round to oval morphology, a visible nucleus (DAPI positive), positive staining for cytokeratin
and negative staining for CD45. 
 In contrast to other analytical platforms (e.g., flow cytometry, hematology analyzers, and laser scanning cytometry),
only cells identified by the presence of a defined antigen are presented to the optical detection system. That is, if one is for example interested in analyzing the number and signal intensity of circulating tumor cells in blood expressing a
specific marker, magnetic nanoparticles and antibodies against that marker labeled with fluorescent dyes are employed to mark the cells of interest. Those particular cells that express the antigen of interest will be isolated from blood under the
influence of the system’s magnetic gradient and present themselves to the optical detection system. Consequently, isolation of cells of interest can be performed in the presence of all blood constituents (including treatment drugs). Thus, this
platform has advantages over traditional flow cytometry in that objects of interest can be visualized [**]. 
  

	**	Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under
Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. 

 Proposal 
 We seek to
establish a research agreement with Immunicon to development and validation of specified methods for the analysis of rare circulating cells in the blood. Potential rare circulating cells are tumor cells, endothelial cells and precursors, tumor
antigen specific immune cells, and antigen presenting cells, among others. 
 Pfizer Inc will select clinical sites and investigators for the development and
validation of these methodologies, as well as provide clinical funding and monitoring for the projects as part of the overall proposal. 
 Materials and
equipment will be provided by Immunicon. 
 Cost (2004-2006) 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 [**] 
 Proposal Objectives AND Timelines 
 For the duration of the Pfizer 1002 Study, Immunicon will analyze patient samples as described above. 
  

	**	Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under
Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. 

  

 2 

 Subject Population 
 Inclusion Criteria 
  

	 	•	 	Disease related 

  

	1.	[**] 

  

	2.	[**] 

  

	3.	[**] 

  

	 	•	 	Prior/Concurrent Therapy 

  

	1.	[**] 

  

	2.	[**] 

  

	3.	[**] 

  

	4.	[**] 

  

	5.	[**] 

  

	6.	[**] 

  

	 	•	 	Patient related 

  

	1.	[**] 

  

	2.	[**] 

  

	3.	[**] 

  

	4.	[**] 

  

	5.	[**] 

  

	6.	[**] 

  

	7.	[**] 

  

	8.	[**] 

  

	9.	Written and voluntary informed consent. 

  

	**	Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under
Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. 

  

 3 

 Exclusion Criteria 
  

	1.	[**] 

  

	2.	[**] 

  

	3.	[**] 

  

	4.	[**] 

  

	5.	[**] 

  

	6.	[**] 

  

	7.	[**] 

  

	8.	[**] 

  

	9.	[**] 

  

	10.	[**] 

 Specimen Collection and Handling 
 1. SPECIMEN COLLECTION: 
 The blood will be
drawn by a physician, registered nurse or a licensed phlebotomist at the clinical site. A maximum of [**] of peripheral blood will be drawn from each patient. The blood will be collected into properly labeled 10mL CellSaveTM evacuated blood collection tubes (minimum of [**] of
blood per tube). 
 2. SHIPPING AND HANDLING OF SPECIMENS: 
 The CellSaveTM tubes must be maintained at ambient (10-30°C) temperature, avoiding extremes of heat and cold, at all times. The tubes must be shipped overnight to Immunicon on the same date as the
draw. 
 Laboratory Contact Information: 
 C/o [**] 

Immunicon – Clinical Services 
 3401 Masons Mill Road, Suite 100

 Huntingdon Valley, PA19006-3574 
 Phone:215-8300751 ext. [**]

  

	**	Certain information in this exhibit has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under
Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934. 

  

 4Amended Letter of Agreement

 Exhibit 10.55 
 March 6, 2006 
 Dr. Nicholas A Saccamano, 
 Senior Vice President, 
 Global Research Technology, 
 Pfizer Inc., 
 50 Pequot Avenue, 
 New London, CT 06320 
 RE: Third Amending
Letter of Agreement between Pfizer Inc. and Immunicon Corporation 
 Dear Dr Saccamano: 
 Immunicon Corporation (“Immunicon”) wishes to amend the agreement between Pfizer Inc. and its Affiliates (“Pfizer”) and Immunicon, executed on February 10, 2003 having a termination date of
February 10, 2004, which was amended effective March 23, 2004 to terminate on February 10, 2005, and subsequently amended by a Second Amending Letter of Agreement dated December 12, 2004, to terminate the sooner of
February 10, 2006 or the end of the clinical research study contemplated in the revised Appendix A under the agreement (as amended, the “2003 Agreement”). The Term of the 2003 Agreement terminated on February 10, 2006, since the
clinical research study referred to above had not ended as of that date. However, as samples for the clinical research study have continued to be processed by Immunicon, we now wish to further extend the Term of the 2003 Agreement to the termination
of the clinical research study contemplated in the revised Appendix A. For clarity, this extension is provided to finish the work contemplated in the Agreement and not to conduct new work. 
 All other terms and conditions of the 2003 Agreement, except as set forth above, shall remain unchanged and in full force and effect for the remainder of the Term as
herein extended. 
 If you are in agreement with the foregoing, please so indicate by signing duplicate copies of this letter in the space provided below,
and return one fully signed copy to us, to the attention of Dr. Avijit Roy, Director, Business Development. 
  

									
	 Sincerely,
	 		 	
			
	 Immunicon Corporation
	 		 	 Acknowledged and Agreed:

	 /s/ Byron D. Hewett
	 		 	 Pfizer Inc.

	 Byron D. Hewett
	 		 	
					
		 		 		 	By:	 	 /s/ Dr. Nicholas A. Saccamano

		 		 		 	 Name:
	 	 Dr. Nicholas A. Saccamano

	 President and CEO
	 		 	 Title:
	 	 SVP—Global Research Technology

		 		 		 	 Date:
	 	 March 7, 2006

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]